There has been a change to the Prescribing Information. Click here to see changes.
>If endometriosis pain
has her on the sidelines,
ORILISSA has been prescribed for over 50,000 patients2*
*These data reflect the number of women prescribed since ORILISSA was FDA approved in July 2018. Data sourced as of June 2020.
ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis.
These are not all the possible side effects of ORILISSA.
Safety and effectiveness of ORILISSA in patients less than 18 years of age have not been established.
US-ORIL-200330
For more information, please click here for full Prescribing Information.
1. ORILISSA [package insert]. North Chicago, IL: AbbVie Inc. 2. Data on file. AbbVie Inc. IQVIA and UBC/Medvantx. August 2018-June 2020.